3147-50-0 Usage
Uses
Used in Pharmaceutical Industry:
2,6-Dihydroxybenzamide is used as an intermediate in the synthesis of various pharmaceuticals for its potential therapeutic applications. Its unique chemical structure allows it to be a key component in the development of new drugs and medications.
Used in Organic Compounds Synthesis:
As a versatile chemical compound, 2,6-dihydroxybenzamide is used as an intermediate in the synthesis of a wide range of organic compounds. Its reactivity and functional groups make it a valuable building block for creating complex organic molecules.
Used in Laboratory Research:
2,6-Dihydroxybenzamide is utilized as a reagent in laboratory research, where its unique properties can be explored and studied. Researchers can use 2,6-DIHYDROXYBENZAMIDE to investigate various chemical reactions and mechanisms, contributing to the advancement of scientific knowledge.
Used in Chemical Product Production:
2,6-Dihydroxybenzamide serves as a precursor in the production of various chemical products. Its versatility and reactivity make it a valuable component in the synthesis of a range of chemical products, including dyes, pigments, and other specialty chemicals.
Used in Medicine:
Due to its potential applications in the medical field, 2,6-dihydroxybenzamide is used in the development of new therapeutic agents. Its unique chemical structure and properties may contribute to the discovery of novel treatments for various diseases and conditions.
Used in Agriculture:
2,6-Dihydroxybenzamide has potential applications in agriculture, where it can be used in the development of new agrochemicals or as a component in existing products. Its unique properties may contribute to the improvement of crop protection and yield enhancement.
Used in Material Science:
In the field of material science, 2,6-dihydroxybenzamide can be used to develop new materials with specific properties. Its unique chemical structure may contribute to the creation of advanced materials with applications in various industries, such as electronics, textiles, and coatings.
Check Digit Verification of cas no
The CAS Registry Mumber 3147-50-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,1,4 and 7 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 3147-50:
(6*3)+(5*1)+(4*4)+(3*7)+(2*5)+(1*0)=70
70 % 10 = 0
So 3147-50-0 is a valid CAS Registry Number.
InChI:InChI=1/C7H7NO3/c8-7(11)6-4(9)2-1-3-5(6)10/h1-3,9-10H,(H2,8,11)
3147-50-0Relevant academic research and scientific papers
PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS
-
, (2010/03/02)
The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.
Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent
Neale, Jason R.,Richter, Natali B.,Merten, Kevyn E.,Grant Taylor,Singh, Sujan,Waite, Leonard C.,Emery, Nicole K.,Smith, Ned B.,Cai, Jian,Pierce Jr., William M.
supporting information; experimental part, p. 680 - 683 (2009/09/06)
In this study a novel bone-targeting agent containing elements of the tricarbonylmethane system of ring A of tetracycline was developed and was shown to bind to the mineral constituent of bone, hydroxyapatite. Conjugation of this bone-targeting agent to estradiol resulted in a bone-targeted estrogen (BTE2-A1) with an enhanced ability to bind to hydroxyapatite. In an ovariectomized rat model of osteoporosis a partial separation of the skeletal effects of estradiol from the uterine effects was observed following subcutaneous administration of BTE2-A1. This novel bone-targeting estradiol delivery system has the potential to improve the safety profile of estradiol in the treatment of osteoporosis.
Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders
-
Page/Page column 13, (2010/02/12)
The present invention relates to compounds of the formula or pharmaceutically acceptable salts thereof useful for the prophylaxis and treatment of degenerative bone disorders and for the acceleration of bone healing.
